Kinnate Biopharma Inc (KNTE) is down Thursday morning, with the stock losing -100.00% in pre-market trading to . KNTE's short-term technical score of 73 indicates that the stock has traded more bullishly over the last month than 73% of stocks on the market. In the Biotechnology industry, which ranks 119 out of 146 industries, the stock ranks higher than 82% of stocks. Kinnate Biopharma Inc has risen 92.31% over the past month, closing at $1.21 on October 19. During this period of time, the stock fell as low as $1.07 and as high as $1.61. KNTE has an average analyst recommendation of Buy. The company has an average price target of $6.58.
KNTE has an Overall Score of 79. Find out what this means to you and get the rest of the rankings on KNTE!